Forma Therapeutics, Inc.

Abbvie Inc.

Novo Nordisk Healthcare Ag

Abbott Laboratories Corporation

Forma Tm2, Inc.

Bristol-myers Squibb Compnay

Other

Basf Aktiengesellschaft

Abbott Gmbh & Co Kg

Valo Health, Inc.

Valo Early Discovery, Inc.

Makoto, Aoyama

Anna M Ericsson

David R Lancia, Jr

Gary Gustafson

Zhongguo Wang

Ann-Marie Campbell

Justin Andrew Caravella

R Bruce Diebold

Jian Lin

Susan Ashwell

Wei Lu

David James Richard

Neal Green

Michael Michaelides

Xiaozhang Zheng

Steven Gregory Mischke

Shawn E R Schiller

Steven K Davidsen

Tatiana Shelekhin

Hongbin Li

Zhiqin Ji

Yujia Dai

Angela V West

Bingsong Han

Chase C Smith

Alexandre Joseph Buckmelter

Stephanos Ioannidis

Adam Charles Talbot

Minghua Wang

Kristine E Frank

Bruce Follows

David Joseph Guerin

David J Calderwood

Gary Marshall

Darby Schmidt

Lee Daniel Arnold

Michael M Friedman

Kevin R Woller

Anne Marinier

Michael Morytko

Stevan Wakefield Djuric

Alain Martel

Michael L Friedman

Lorna Mitchell

Torsten Herbertz

Bradford Graves

Biqin C Li

Lu Wang

Kresna Hartandi

Jennifer R Downing

Dawn M George

Maria A Argiriadi

Neil Wishart

Nathan Josephsohn

Eric R Goedken

Kent D Stewart

Richard W Dixon

Paul Rafferty

Fred Christopher Zusi

Jeffrey W Voss

Kelly Mullen

Kevin Patrick Cusack

Grier A Wallace

Graham K Ansell

Bryan A Fiamengo

John E Starrett, Jr

Alan Frank Gasiecki

Thomas D Gordon

James H Holms

Michael Z Hoemann

Irini Akritopoulou-Zanze

Douglas H Steinman

Eric C Breinlinger

David Wayne Borhani

Henry Q Zhang

Carol K Wada

Kenneth M Tramposch

Robert V Talanian

Andrew Burchat

Patrick F Kelly

Michael R Michaelides

Zhiren Xia

Peter R Reczek

Makoto Takeshita

Xiaoyun Wu

Melanie A Muckey

Xina Nair

Gagandeep K Somal

Vijaya J Gracias

Claude E Barberis

Jürgen Dinges

Kevin James Doyle

Robert W Steele

Barbara F Scott

Kimba Lee Fischer

Madhu Mondal

Michael Hockley

David J Wilkins

Lily K Abbott

Xiaolei Zhang

The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of the CBP/p300 family of bromodomains. For instance, the disclosure is concerned with compounds and compositions for inhibition of the CBP/p300 family of bromodomains, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of CBP/p300 family of bromodomains, and methods of synthesis of these compounds.

Inhibiting CREB binding protein (CBP)

The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of the CBP/p300 family of bromodomains. For instance, the disclosure is concerned with compounds and compositions for inhibition of the CBP/p300 family of bromodomains, methods of treating diseases or disorders associated with the inhibition of CBP/p300 family of bromodomains (e.g., certain forms of cancer), and methods of synthesis of these compounds.

Inhibiting cyclic AMP-responsive element-binding protein (CREB)

The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, U, W, W, W, R-R, and Rare described herein.

Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors

The compound (S)-1-(5-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-hydroxy-2-phenylpropan-1-one, or a pharmaceutically acceptable salt thereof, is useful to increase the affinity of hemoglobin for oxygen. Methods and compositions for the treatment of a hemoglobinopathies are provided herein, including certain pharmaceutical compositions for activating PKR.

Activating pyruvate kinase R

The disclosure provides novel chemical compounds useful as activators of PKR. PKR activating compounds are useful in the treatment of disease and disorders associated with modulation of PKR and/or PKM2, such as pyruvate kinase deficiency (PKD).

The disclosure relates to modulating pyruvate kinase and provides novel chemical compounds useful as activators of PKR, as well as various uses of these compounds. PKR activating compounds are useful in the treatment of diseases and disorders associated with PKR and/or PKM2, such as pyruvate kinase deficiency (PKD), sickle cell disease (SCD), and thalassemia.

Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators

Compounds that activate pyruvate kinase R can be used for the treatment of sickle cell disease (SCD). Methods and compositions for the treatment of SCD are provided herein, including a therapeutic compound designated as Compound 1.

Treating sickle cell disease with a pyruvate kinase R activating compound

The invention relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula: where m, n, X, X, R-R, Rand Rare described herein.

Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors

This disclosure provides compounds and compositions for activating pyruvate kinase R (PKR) and related methods of manufacturing and using these compounds and compositions.

Methods for treating certain androgen receptor-positive forms of cancer using inhibitors of the CREB binding protein bromodomain are disclosed. In some methods, the AR-positive forms of cancer may be breast cancer, including triple negative forms, hormone receptor positive forms, and HER2-positive forms. In other methods, the AR-positive forms of cancer may be prostate cancer, including metastatic castration resistant prostate cancer. In some embodiments, methods of treating prostate cancer comprise the step of administering to a patient in need thereof the compound (1R,3R)-3-[(7S)-2-[(R)-(5-fluoro-2-methoxyphenyl)(hydroxy)methyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexane-1-carboxylic acid, or a pharmaceutically acceptable salt thereof.

Bromodomain inhibitors for androgen receptor-driven cancers

Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors

Growing community of inventors

Schrewsbury, MA, United States of America

Anna M Ericsson